18 and older, any sex, with Retinal Vein Occlusion. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Primary Outcome is the Comparison Between the Minocycline and Placebo Groups of the Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months Compared to Baseline.Primary· Baseline to Month 12
The primary outcome measure is the mean change in best-corrected visual acuity (BCVA), as measured in ETDRS letters in the study eye at 12 months compared to baseline. Values presented represent mean and standard deviation of change from baseline at 12 months.
Group
Value
95% CI
Minocycline
13.3
± 7.0
Placebo
-2.0
± NA
Number of Participants Improving ≥ 1 logOCT Scale Step in the Study Eye at 12 Months Compared to BaselineSecondary· Baseline to Month 12
Improvement of ≥ 1 logOCT scale step is defined as a decrease of ≥ 1-step on the logOCT scale. A 1-step decrease is equivalent to at least a 20% improvement of central macular thickness.
Group
Value
95% CI
Minocycline
2
Placebo
2
Number of Participants Improving ≥ 1 logOCT Scale Step in the Study Eye at 24 Months Compared to BaselineSecondary· Baseline to Month 24
Improvement of ≥ 1 logOCT scale step is defined as a decrease of ≥ 1-step on the logOCT scale. A 1-step decrease is equivalent to at least a 20% improvement of central macular thickness.
Group
Value
95% CI
Minocycline
2
Placebo
2
Number of Bevacizumab Injections From Baseline to 12 MonthsSecondary· Baseline to Month 12
The outcome measure is the number of bevacizumab injections administered to participants between baseline and 12 months.
Group
Value
95% CI
Minocycline
5.5
± 4.4
Placebo
10.5
± 0.7
Number of Bevacizumab Injections From Baseline to 24 MonthsSecondary· Baseline to Month 24
The outcome measure is the number of bevacizumab injections administered to participants between baseline and 24 months.
Group
Value
95% CI
Minocycline
7.8
± 8.8
Placebo
16.0
± 0.0
Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 3 Months Compared to BaselineSecondary· Baseline to Month 3
The outcome measure is the mean change in macular sensitivity in the study eye at 3 months compared to baseline. Values presented represent mean and standard deviation of change from baseline at 3 months.
Group
Value
95% CI
Minocycline
0.8
± 2.2
Placebo
3.4
± 0.2
Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 6 Months Compared to BaselineSecondary· Baseline to Month 6
The outcome measure is the mean change in macular sensitivity in the study eye at 6 months compared to baseline. Values presented represent mean and standard deviation of change from baseline at 6 months.
Group
Value
95% CI
Minocycline
0.3
± 2.8
Placebo
1.1
± 4.5
Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 12 Months Compared to BaselineSecondary· Baseline to Month 12
The outcome measure is the mean change in macular sensitivity in the study eye at 12 months compared to baseline. Values presented represent mean and standard deviation of change from baseline at 12 months.
Group
Value
95% CI
Minocycline
-1.7
± 5.5
Placebo
1.3
± 0.6
Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 18 Months Compared to BaselineSecondary· Baseline to Month 18
The outcome measure is the mean change in macular sensitivity in the study eye at 18 months compared to baseline. Values presented represent mean and standard deviation of change from baseline at 18 months.
Group
Value
95% CI
Minocycline
-0.9
± 4.0
Placebo
4.5
± 0.3
Changes in Mean Macular Sensitivity in the Study Eye as Measured by Microperimetry at 24 Months Compared to BaselineSecondary· Baseline to Month 24
The outcome measure is the mean change in macular sensitivity in the study eye at 24 months compared to baseline. Values presented represent mean and standard deviation of change from baseline at 24 months.
Group
Value
95% CI
Minocycline
-1.5
± 3.3
Placebo
3.9
± 4.2
Mean Change in the ETDRS BCVA in the Study Eye at 24 Months Compared to BaselineSecondary· Baseline to Month 24
The outcome measure is the mean change in best-corrected visual acuity (BCVA), as measured in ETDRS letters in the study eye at 24 months compared to baseline. Values presented represent mean and standard deviation of change from baseline at 24 months.
Group
Value
95% CI
Minocycline
13
± 0.0
Placebo
-17.0
± NA
Changes in Retinal Thickness in the Study Eye as Measured by Optical Coherence Tomography (OCT) at 6 Months Compared to BaselineSecondary· Baseline to Month 6
The outcome measure is the mean change in central retinal thickness in the study eye at 6 months compared to baseline. Values presented represent mean and standard deviation of change from baseline at 6 months.
Group
Value
95% CI
Minocycline
-272.7
± 117.0
Placebo
-312.0
± 128.7
Adverse events — posted to ClinicalTrials.gov
Time frame: 24 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Background:
\- Central retinal vein occlusion (CRVO) is a blockage of the main vein that carries blood away from the retina in the back of the eye. It can lead to macular edema, a swelling of the retina that is a common source of vision loss. Studies suggest that inflammation might be a cause. Minocycline is a drug that might help prevent cells involved in inflammation from becoming activated. It is approved for use as an antibiotic, but it has not yet been tested to see if it can treat CRVO.
Objectives:
\- To test the safety and effectiveness of minocycline as a treatment for central retinal vein occlusion.
Eligibility:
\- Individuals at least 18 years of age who have central retinal vein occlusion in at least one eye, with vision between 20/32 and 20/200.
Design:
* This study lasts 2 years, with at least 25 visits.
* Participants will be screened with a physical exam and medical history. They will also have blood tests and an eye exam. One eye will be selected as the study eye to receive the medicine.
* Participants will take minocycline or a placebo pill twice a day, about 12 hours apart, for 2 years.
* Participants will have monthly visits for blood tests and full eye exams to study the effect of the treatment. Other exams may include thyroid tests and eye imaging studies. Those in the study may also receive injections of a drug to prevent the growth of new blood vessels in the eye.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
· Phase 1
· not yet recruiting
NCT07305896 — Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage
· NA
· not yet recruiting
NCT07068607 — Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradicatio
· Phase 4
· recruiting
NCT06523764 — Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment
· Phase 4
· active not recruiting
NCT06120140 — Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small
· Phase 2
· recruiting
Other recruiting trials for Retinal Vein Occlusion
Currently open trials in the same condition.
NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience
· NA
· recruiting
NCT06439576 — Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Relat
· recruiting
NCT07106268 — Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema
· active not recruiting
NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
· active not recruiting
NCT04505618 — Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
· NA
· recruiting
Other National Eye Institute (NEI) trials
Trials by the same sponsor.
NCT06491615 — National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and
· recruiting
NCT04289571 — Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
· Phase 1
· recruiting
NCT04833361 — Potential Environmental Causes of Uveal Coloboma
· completed
NCT06670989 — Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss
· NA
· active not recruiting
NCT04591483 — Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Eye Institute (NEI)
Last refreshed: 17 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01468844.